Drug intelligence / Profile preview

gloriosine

Development stage
Preclinical
Lead developer
Indian Institute of Technology Varanasi
Modality
Small Molecules
01

Overview

Gloriosine is a colchicine-like natural alkaloid isolated from the roots of *Gloriosa superba* (glory lily). Structurally identified as N-deacetyl-N-formylcolchicine, gloriosine acts as a microtubule-targeting agent that binds to the colchicine-binding site of tubulin, disrupting microtubule polymerization and arresting the cell cycle at the G2/M phase. In addition to its antimitotic properties, gloriosine has been shown to induce autophagic cell death in non-small cell lung cancer (NSCLC) cells by negatively regulating Yes-associated protein (YAP) transcriptional activity, which subsequently suppresses the AKT/mTOR pathway. In triple-negative breast cancer (TNBC) models, gloriosine also downregulates glutaminase 1 (GLS1), suppressing glutamine metabolism and inducing ferroptosis. It is currently being investigated in preclinical research as a potential anticancer therapeutic candidate with lower toxicity to normal cells compared to colchicine.

Other names
Colchicine EP Impurity AColchicine impurity AN-deacetyl-N-formyl-colchicineN-deacetyl-N-formylcolchicineN-formyl-N-deacetylcolchicineN-formyldeacetylcolchicineN-formyldesacetylcolchicine
02

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on gloriosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gloriosine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call